Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 14, 2023, Ultragenyx Pharmaceutical Inc. (the "Company") announced that
Camille L. Bedrosian, M.D., the Company's Executive Vice President and Chief
Medical Officer, will be transitioning to a new role as Strategic Development
Advisor to the Company, effective May 1, 2023 (the "Effective Date"). Eric
Crombez, M.D., the Company's current Chief Medical Officer for Gene Therapy and
Inborn Errors of Metabolism, will assume the role of Executive Vice President,
Chief Medical Officer, effective as of the Effective Date.
In connection with Dr. Bedrosian's new role, the Company and Dr. Bedrosian are
expected to amend the Offer Letter, dated as of January 15, 2018, as amended
between the Company and Dr. Bedrosian (the "Offer Letter"), which will provide
for a new base salary of $500,000, target bonus of 35% of her base salary and
target 2023 equity award of 6,900 shares of restricted stock units and 9,200
stock options, in each case to be effective on or about the Effective Date. The
Offer Letter is also expected to be amended to provide that in the event Dr.
Bedrosian is terminated by the Company without Cause (as defined in the Offer
Letter) or if Dr. Bedrosian resigns due to a Constructive Termination (as
defined in the Offer Letter), she will be entitled to receive the severance
benefits provided for under the Offer Letter based on her current base salary of
$600,000 and target bonus of 50% of her base salary (if such termination or
resignation occurs on or before May 1, 2024) or based on her base salary and
target bonus amount then in effect at the time of termination or resignation, if
such termination or resignation occurs after May 1, 2024.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ULTRAGENYX PHARMACEUTICAL INC. 
